Sign in

    Bill Bonello

    Senior Research Analyst at Craig-Hallum Capital Group LLC

    Bill Bonello is a Senior Research Analyst at Craig-Hallum Capital Group, specializing in healthcare equity research with a focus on diagnostics and life sciences companies. He covers prominent firms such as Natera, NeoGenomics, and LabCorp, applying over 25 years of industry and capital markets expertise that has contributed to his strong track record in sector analysis and client advisory. Bonello began his financial research career after holding leadership roles including Chief Strategy Officer and CFO at NeoGenomics and SVP of Investor Relations at LabCorp, previously working at RBC Capital Markets, Wachovia Securities, and Piper Jaffray, and first joined Craig-Hallum in 2012 before rejoining after industry experience. He holds a BA from Carleton College, an MBA from Northwestern’s Kellogg School of Management, and maintains professional securities credentials required for equity analyst roles.

    Bill Bonello's questions to BIODESIX (BDSX) leadership

    Bill Bonello's questions to BIODESIX (BDSX) leadership • Q2 2025

    Question

    Bill Bonello of Craig-Hallum Capital Group LLC asked for a breakdown of the path to adjusted EBITDA positivity in Q4, questioning the mix of revenue leverage and cost-cutting. He also sought clarity on whether second-half revenue growth would be driven by volume or ASP, and inquired about the outlook for Development Services revenue.

    Answer

    Robin Harper Cowie, CFO, clarified that the path to Q4 adjusted EBITDA positivity is primarily driven by revenue growth, fueled by the planned sales team expansion to 93-97 reps. She stated there are no major cost-cutting measures planned. Cowie confirmed that the expected revenue acceleration is rep and volume-driven, with stable ASPs, and noted that Development Services revenue typically sees a seasonal uptick in the fourth quarter.

    Ask Fintool Equity Research AI

    Bill Bonello's questions to SOPHiA GENETICS (SOPH) leadership

    Bill Bonello's questions to SOPHiA GENETICS (SOPH) leadership • Q2 2025

    Question

    Bill Bonello of Craig-Hallum Capital Group LLC sought details on the AstraZeneca contract structure, asking if it was milestone-based, if milestones were within Sophia's control, and if it could generate ongoing revenue. He also attempted to clarify the deal's potential size and asked about the terms of the Perceptive financing.

    Answer

    President Ross Muken confirmed the AstraZeneca deal has a mix of base payments and milestone 'bullets' tied to deliverables, not clinical risk, and that it's too early to discuss potential ongoing products. He declined to size the deal but affirmed its materiality. EVP & CFO George Cardoza detailed the Perceptive financing terms as SOFR plus 6%, along with the issuance of warrants.

    Ask Fintool Equity Research AI

    Bill Bonello's questions to Guardant Health (GH) leadership

    Bill Bonello's questions to Guardant Health (GH) leadership • Q2 2025

    Question

    Bill Bonello of Craig-Hallum Capital Group LLC asked for a big-picture perspective on whether the paradigm shift from tissue-first to liquid-first seen with Guardant360 could be extrapolated to the MRD space, shifting perceptions of Reveal's tumor-naive approach versus tumor-informed tests.

    Answer

    Chairman & Co-CEO Helmy Eltoukhy agreed with the analogy, suggesting it's an underappreciated aspect of the Infinity platform. He explained that features from Guardant360 will migrate to Reveal, creating a differentiated product that analyzes active tumor biology, not just passenger mutations. He believes this will lead to two distinct MRD markets—tumor-informed and a 'massive' tissue-free market—similar to the dynamic in therapy selection, where liquid biopsy is becoming dominant.

    Ask Fintool Equity Research AI

    Bill Bonello's questions to MYRIAD GENETICS (MYGN) leadership

    Bill Bonello's questions to MYRIAD GENETICS (MYGN) leadership • Q4 2024

    Question

    Bill Bonello questioned the timing of the CEO transition and asked for a characterization of the Q1 outlook, noting that the commentary suggested a potentially slower start to the year than investors might have hoped for.

    Answer

    CEO Paul Diaz clarified that the transition timing was driven by a personal career opportunity and expressed his full confidence in the remaining team and strategy. Regarding Q1, CFO Scott Leffler highlighted a difficult year-over-year comparison due to a significant favorable prior-period adjustment in Q1 2024. COO Samraat Raha added that their view of the full year and typical Q1 seasonality (impacted by deductibles) remains unchanged.

    Ask Fintool Equity Research AI